Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their glucose levels as compared to an HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours. SugarBEAT® should significantly expand the use of adjunctive CGM among people with diabetes, given it is more non-invasive (not requiring the insertion of a sensor into skin), affordable, and flexible than competitor CGMs.
It is worth nothing that over the two-day period 12-13 Sept. 2018, after NMRD reported positive interim data from the clinic portion of its sugarBEAT® FDA clinical trial, the stock price jumped 63%, reaching a high of $3.50 a share, with volume for the two days almost reaching 5.5 million shares. Again, a CE Mark approval could precipitate an upward move in the stock, because the approval will validate the Company’s technology and open up commercialization opportunities in Europe. The Company announced recently that they expect CE Mark approval in 2018. The European market for diabetes care devices is estimated at $5.16 billion for 2018 (MarketDataForecast.com) and by 2023 is expected to reach $6.7 billion.
Here are some investment highlights from Nemaura’s busy 2018:
Given the large market size ($82 billion) NMRD is targeting, the stock should trade at much higher multiples as they near CE Mark approval and began commercializing sugarBEAT® in Europe. An industry comp is Sensomedics (NYSE American: SENS), whose market cap is $630 million, compared to Nemaura’s market cap of $440 million.
TapImmune Inc. (NASDAQ: TPIV) is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. Its stock is surging in response to a steady stream of good news:
TapImmune is in four active Phase 2 clinical trials (six clinical trials in total) in the $100+ billion market for immunotherapy cancer drugs. The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health), and much of the growth is being driven by constant innovations in cancer immunotherapy. Currently, TapImmune is advancing its robust mid-stage clinical pipeline focused on breast and ovarian cancer.
Similar companies in Phase 2 clinical trials in immuno-oncology have attained much higher valuations, as for example Aduro BioTech (NASDAQ: ADRO) at $520 million. TapImmune is valued at only $120 million. With its next-generation T-cell vaccine technology, the Company is well-positioned to capture part of the rapidly growing cancer immunotherapy market.
Immuron Limited (NASDAQ: IMRN) is an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Here are some reasons 2018 has been so good for IMRN:
The company is in three Phase 2 clinical trials for NASH, ASH, and pediatric NAFLD. Another clinical stage asset, IMM-529, is targeting Clostridium difficile infections (CDI). These products, together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the global immunotherapy market.
Other companies in Phase 2 trials for NASH have achieved significant valuations.Intercept Pharmaceuticals had positive Phase 2 results for NASH, leading to an increase in market cap from $1.5 billion to $6.6 billion. Additionally, companies such as Galectin Therapeutics (NASDAQ: GALT; market cap: $200 million), Galmed Pharmaceuticals (NASDAQ: GLMD; $250 million), Conatus Pharmaceuticals (NASDAQ: CNAT; $150 million), and Genfit SA (OTCQB: GNFTF; $660 million), are in Phase 2 clinical trials for NASH and have valuations much higher than Immuron’s ($30 million).